Third Peer-Reviewed Study Proves Botanical Formula Fights Prostate Cancer Without Toxicity
Santa Rosa, Calif. (February 8, 2012) — Scientists at Indiana University, Methodist Research Institute, study a botanical formula that kills aggressive prostate cancer tumors. Their findings, based on experiments in mice using a human prostate cancer tumor model, appear online in The International Journal of Oncology. This is the third published study from a major university to show significant results of this specific multi-nutrient prostate formula against the invasive behavior of aggressive prostate cancer cells, tumor growth and metastasis. The formula combines botanical extracts, phytonutrients, botanically-enhanced medicinal mushrooms, and antioxidants. (Learn more about the formula by visiting www.prostatehealthsolutions.org)
Lead researcher, Dr. Daniel Sliva says, “Multiple studies demonstrate that this prostate formula is a possible treatment for hormone refractory (androgen independent) prostate cancer.”
Suppresses Aggressive Tumor Growth Without Toxicity
Results of the study show this prostate formula significantly suppressed tumor growth in aggressive, hormone refractory (androgen independent) human-prostate cancer cells. This study also analyzed the formula for potential toxicity, demonstrating it to be safe with no signs of toxicity at the highest dosages. (To view the study on Pubmed, visit www.ncbi.nlm.nih.gov/pubmed/22293856)
Researcher and formulator, Dr. Isaac Eliaz says, “This study is a milestone in the research of this formula, demonstrating its safety and effectiveness in treating human prostate cancer in an animal model. These positive results offer a significant contribution to the field of prostate cancer research, and add to the growing body of published data substantiating the role of natural compounds in the treatment of prostate cancer.”
Results of the study show that the oral administration of the formula produced a statistically significant 27% suppression of tumor growth, compared to controls. The study was performed using a xenograft tumor model of human prostate cancer in mice.
Inhibits Genes Involved in Tumor Growth and Metastasis
Even more important, in addition to significant reduction in tumor volume, results showed inhibition of the expression of several genes involved in cancer proliferation and metastasis. Three prostate cancer-related genes (IGF2, NRNF2 and PLAU/uPA) that were suppressed by this formula not only control aggressive prostate tumor growth, but also relate to the metastatic potential. It is metastasis that makes prostate cancer deadly. The formula also significantly increased the expression of a gene that fights against prostate cancer, CDKN1A, which works by specifically inhibiting other cancer-promoting cellular mechanisms.
By suppressing specific genes related to aggressive prostate cancer growth and proliferation, and increasing the expression of cancer-fighting genes, this integrative formula demonstrated multiple anti-cancer mechanisms and genetic targets. This pre-clinical in vivo study confirms previously published in vitro data, which also shows the ability of this formula to decrease the expression of PLAU/uPA genes in aggressive, hormone-independent prostate cancer cells.
Study Further Validates Earlier Results
This formula was previously studied at research laboratories at Columbia University, New York, NY and at the Cancer Research Laboratory, Methodist Research Institute, Indiana University Health, Indianapolis, IN. These published studies showed significant results in this formula’s ability to inhibit prostate cancer growth and proliferation.
“In summary, this dietary supplement is a natural compound for the possible therapy of human hormone refractory (independent) prostate cancer,” says Dr. Sliva. Ongoing research on this formula in prostate cancer models continues to show encouraging results, and additional studies are forthcoming.
For more information about this groundbreaking study or to interview Dr. Isaac Eliaz, call (707) 583-8622 or email amy@dreliaz.org.
Source:
ProstaCaid™ inhibits tumor growth in a xenograft model of human prostate cancer (http://www.ncbi.nlm.nih.gov/pubmed/22293856)
About Better Health Publishing:
Better Health Publishing (BHP) focuses on the publication of key works promoting health and wellness. BHP believes that education and accessible information are the core components of a healthy and sustainable society.
Contact:
Amy Pellegrini
Communications Specialist
Better Health Publishing
(707) 583-8622
amy@dreliaz.org
Tags: